Mechanism of Wuling powder modulating proBDNF/p75NTR/sortilin and BDNF/TrkB pathways in the treatment of ulcerative colitis complicated with depression

Figure 7 Expression of tumor necrosis factor-alpha and interleukin-6 mRNA in colonic tissue after treatment. A: Expression of tumor necrosis factor-alpha mRNA in depression groups; B: Expression of tumor necrosis factor-alpha mRNA in chronic restraint stress, dextran sodium sulfate and compound model groups; C: Expression of interleukin-6 mRNA in depression groups; D: Expression of interleukin-6 mRNA in chronic restraint stress, dextran sodium sulfate and compound model groups. ^aP < 0.01 vs control group; ^bP < 0.01 vs chronic restraint stress group; ^cP < 0.01 vs chronic restraint stress + dextran sodium sulfate group; ^fP < 0.05 vs control group; ^gP < 0.05 vs chronic restraint stress group; ^hP < 0.05 vs chronic restraint stress + dextran sodium sulfate group; ^jP < 0.05 vs dextran sodium sulfate group. CUMS: Chronic restraint stress; DSS: Dextran sodium sulfate; LD: Low-dose Wuling powder; MD: Medium-dose Wuling powder; HD: High-dose Wuling powder; FLU: Fluoxetine; MS: Mesalazine; TNF: Tumor necrosis factor; IL: Interleukin.